18results about How to "Improve kidney function" patented technology

The present invention belongs to the field of biomedicine, and specifically relates to a new use of Keratin 7 protein, and a recombinant plasmid expressing Keratin 7 protein, a recombinant probiotic expressing Keratin 7 protein, and a use for preparing a medicine for treating and / or preventing metabolic diseases. The present invention first inserts the Keratin 7 gene into the expression vector pET‑28a to obtain a recombinant plasmid expressing Keratin 7; secondly, the recombinant plasmid is introduced into Escherichia coli Nissle 1917 (EcN) tolerant bacteria to obtain a functional recombinant probiotic. The recombinant probiotics described in the present invention can effectively reduce blood sugar while efficiently expressing Keratin 7 protein, and has a significant therapeutic effect on diabetes and its complications, and the effect is higher than that of clinical drugs, and has good clinical application prospects.

The invention discloses a novel pharmaceutical application of hepcidin, particularly relates to an application of hepcidin in preparation of drugs for blocking acute kidney injury collecting tube ferroptosis and protecting renal functions, and belongs to the technical field of medicines. It is proved for the first time that both the kidney endogenous hepcidin and the exogenous hepcidin can inhibit the ferreath of the collecting tube cells, so that the tubule injury caused when the acute kidney injury is induced by ischemia-reperfusion is relieved, and the kidney function is improved. The invention opens up a new medical approach for the treatment of acute kidney injury; furthermore, the invention discloses a medicine for relieving ischemia reperfusion induced acute kidney injury collecting tube ferroptosis and protecting renal function, and the medicine is an intraperitoneal injection and is prepared by dissolving hepcidin with therapeutic concentration by using PBS (Phosphate Buffer Solution).

The invention provides egg cordyceps sinensis and a cultivation method thereof. The cultivation method comprises the following steps: S1, selecting fresh eggs; s2, forming small holes in the eggshell, stirring yolk through the small holes, and pumping out a certain amount of egg liquid; s3, injecting a sugar aqueous solution into the eggs from which the egg liquid is extracted, and then shaking the eggs to mix the egg liquid with the sterilized sugar aqueous solution; s4, inoculating cordyceps sinensis liquid strains into the mixed eggs, uniformly shaking, and sealing the small holes; s5, the eggs inoculated with the cordyceps sinensis liquid strains are placed in an environment with the temperature being 22-25 DEG C and the humidity being 40-60% to be cultured for 10-30 days; and S6, removing part of eggshells from the cultured eggs, putting the eggs into a disinfected transparent container, fixing, sealing a cover, putting in an environment with the temperature of 20-25 DEG C and the humidity of 65-85%, and culturing under illumination until the eggs grow out and are mature to obtain the egg cordyceps sinensis. The method has the advantages of wide and cheap raw material sources, simplicity in operation, low requirements on a culture environment, short production period and the like, and has good economic benefits.

The invention relates to the technical field of medicines, discloses an application of 18 beta-glycyrrhetinic acid in a TMAO inhibitor, and further discloses an application of 18 beta-glycyrrhetinic acid in preparation of medicines for treating chronic diseases such as chronic kidney disease (CKD) and the like. The invention provides 18 beta-glycyrrhetinic acid (18 beta-GA) which is a substance capable of effectively inhibiting choline in intestinal tracts from being metabolized into TMAO for the first time, and the 18 beta-GA is efficiently combined with CutC / D and FMO to inhibit the generation of TMAO, so that the aggravating effect of TMAO on chronic kidney diseases is relieved; the invention further provides a method for improving kidney diseases through a CXCL12 / CXCR4 signal axis after the TMAO is reduced by the 18 beta-glycyrrhetinic acid, a new thought and a new method are provided for developing medicines for treating the TMAO related diseases, and a new way is expected to be developed for treating the chronic kidney diseases.

The invention relates to a traditional Chinese medicine composition for treating chronic kidney diseases and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: astragalus membranaceus, rheum officinale, cassia twig, poria cocos, radix paeoniae rubra, peach kernels and moutan bark. The traditional Chinese medicine components in the traditional Chinese medicine composition are scientific in compatibility, and the traditional Chinese medicine composition has a very remarkable effect on treating the chronic kidney diseases. Researches show that the traditional Chinese medicine composition can effectively treat the chronic kidney disease, improve the kidney function of a kidney disease patient, reduce the serum creatinine level and the urea nitrogen level, increase the expression level of peroxisome related functional enzymes and relieve kidney pathological injuries.

The invention discloses a traditional Chinese medicine composition for treating kidney diseases, which is prepared from the following eleven medicinal materials: radix rehmanniae recen, artemisia capillaris, radix scutellariae, fructus aurantii, folium eriobotryae, dendrobe, radix ophiopogonis, perilla stem, fructus amomi, cortex magnoliae officinalis and radix salviae miltiorrhizae, the radix rehmanniae recen and the artemisia capillaris are monarch drugs, the radix scutellariae, the fructus aurantii, the folium eriobotryae, the dendrobe, the radix ophiopogonis, the perilla stem and the fructus amomi are ministerial drugs, the cortex magnoliae officinalis and the radix salviae miltiorrhizae are adjuvant drugs, and the radix rehmanniae recen and the fructus amomi are adjuvant drugs. The traditional Chinese medicine composition has the effects of nourishing yin, clearing stomach, resolving dampness and enlivening spleen, and also discloses a medicine for treating kidney diseases, which is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials, and application of the traditional Chinese medicine composition in preparation of the medicine for treating kidney diseases, especially kidney diseases caused by damp-heat impairment of yin. The traditional Chinese medicine composition is used for clearing damp-heat and nourishing yin, has a good clinical curative effect, can improve the renal function and relieve renal injury, and is high in safety and free of toxic and side effects.

The present invention discloses a Chinese medicine composition for treating chronic kidney disease and its application. The Chinese medicine composition comprises 30-50 parts of astragalus, 2-10 parts of leech, 50-70 parts of radix scutellariae, 5-20 parts of seaweed and 5-20 parts of turtle shell. The Chinese medicine composition can be used to prepare a preparation for treating chronic kidney disease. The Chinese medicine composition has a good therapeutic effect on the decrease of glomerular filtration rate and deterioration of renal function caused by chronic kidney disease, especially the increase of creatinine, and can significantly improve the clinical symptoms of patients with chronic kidney disease; it has no obvious damage to liver function and coagulation function, has high safety, and has broad application prospects in the field of chronic kidney disease treatment.

The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for preventing and treating UACR rise and application. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 40-60 parts of radix astragali, 25-35 parts of semen euryales, 18-22 parts of fructus rosae laevigatae, 4-6 parts of leeches, 18-22 parts of caulis sinomenii and 35-55 parts of penthorum chinense pursh. The traditional Chinese medicine composition has the effects of tonifying spleen and kidney and reducing turbid toxins, and has the effect of protecting the liver, so that the safety is relatively high; moreover, the treatment effect on the reduction or reversal of the urine UACR is better, the recovery is faster, and the application prospect in the field of treatment of the diabetic nephropathy at the middle and early stage is wide.

The present invention relates to methods for treating a human patient suffering from acute kidney injury.

The present invention aims to provide a composition for reducing renal function decline or ameliorating renal function and a method of reducing renal function decline or ameliorating renal function. The present invention relates to a composition for reducing renal function decline or ameliorating renal function, the composition containing L-ergothioneine or a salt thereof as an active ingredient.

The application relates to an application of a traditional Chinese medicine composition in a drug for chronic obstructive pulmonary disease, characterized in that the traditional Chinese medicine composition comprises the following components in parts: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Amygdalus 1-100 parts, Notopterygium 1-100 parts, Zingiber officinale 1-100 parts, Pogostemonis 1-100 parts, Perilla 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-160 parts, Atractylodes macrocephala 1-120 parts, Gypsum fibrosum 1-100 parts, Fructus Crataegi 1-100 parts, Fructus Junci 1-100 parts, Fructus Hordei 1-100 parts, Lumbricus 1-100 parts, Radix et Rhizoma Veratri 1-100 parts, Herba Eupatorii Fortunei 1-100 parts, Semen Lepidii 1-100 parts and Semen Platycladi 1-100 parts.

The invention relates to the technical field of polysaccharide medicinal preparations, and particularly discloses a fucoidin-containing composition for chronic nephritis, which comprises the following raw materials: fucoidin, Chinese herbal medicine extract and auxiliary materials. The fucoidin is prepared by the following specific operations: (1) airing and pulping fresh kelp, adding into a tartaric acid solution, grinding for 1-2 hours, adding sodium bicarbonate, stirring, performing electric field pulse treatment for 2-4 minutes in the stirring process, adding a calcium chloride solution, stirring, centrifuging, performing solid-liquid separation, adding trichloroacetic acid into liquid, stirring, centrifuging, and collecting supernate to obtain first supernate; (2) adding a first part of absolute ethyl alcohol into the first supernatant, stirring, standing, centrifuging, and collecting the supernatant to obtain a second supernatant; and adding a second part of absolute ethyl alcohol into the second supernate, stirring, standing, centrifuging, collecting lower-layer precipitate, drying, grinding, adding into deionized water, centrifuging for 1-2 hours, collecting precipitate, washing, and freeze-drying.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating IgA nephropathy proteinuria, a pharmaceutical preparation and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 35 to 45 parts of radix astragali seu hedysari, 35 to 45 parts of rhizoma dioscoreae, 25 to 35 parts of tortoise plastron, 25 to 35 parts of corn stigma, 25 to 35 parts of semen coicis, 10 to 20 parts of fructus ligustri lucidi and 10 to 20 parts of herba ecliptae. According to the present invention, the astragalus membranaceus is adopted as the monarch drug, and is matched with the Chinese yam, the tortoise plastron, the corn stigma, the coix seed, the glossy privet fruit and the eclipta according to the specific ratio, such that the kidney reinforcing and turbidity removing effects are provided, and the kidney function can be improved, the kidney can be protected, and the kidney damage can be prevented while the IgA nephropathy proteinuria can be treated.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a kidney-warming and phlegm-removing preparation for polycystic ovarian syndrome and application of the kidney-warming and phlegm-removing preparation. The kidney-warming and phlegm-cleaning preparation contains amethyst, cistanche deserticola, semen cuscutae, 5.5-22 parts by weight of rhizoma atractylodis, ginger processed pinellia, angelica sinensis, rhizoma cyperi, rhizoma acori graminei, herba epimedii and ligusticum wallichii, and can effectively improve the condition of a patient suffering from kidney deficiency and phlegm-dampness type PCOS, improve the ovarian reserve function and the serum sex hormone secretion condition of the patient and improve the curative effect of the patient. The traditional Chinese medicine composition has great advantages in the treatment of polycystic ovarian syndrome and irregular menstruation, and has good safety and wide market application prospects.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a traditional Chinese medicine composition for treating diabetic nephropathy and application thereof. The traditional Chinese medicine composition is prepared from the following ten medicinal materials according to a specific ratio: radix rehmanniae recen, astragalus membranaceus, golden cypress, coptis chinensis, gastrodia elata, cicada slough, salvia miltiorrhiza, chinaroot greenbrier, rosa laevigata michx and motherwort. Systematic animal experiments and clinical researches prove that the Zuogui blood-glucose-reducing kidney-pleasing formula can effectively reduce fasting blood-glucose of diabetic nephropathy model mice, improve lipid metabolism disorder, remarkably reduce the levels of urea nitrogen, creatinine and uric acid and the ratio of urine protein to creatinine, and can be used for treating diabetic nephropathy by inhibiting expression of fibrosis-related factors such as TGF-beta and alpha-SMA. The renal fibrosis process is delayed. Compared with the prior art, the pharmaceutical composition provided by the invention has remarkable advantages in the aspects of improving renal functions, inhibiting renal tissue fibrosis and delaying the development of diabetic nephropathy.

The invention relates to the technical field of medicines, and discloses application of lactobacillus plantarum GUANKE in prevention and treatment of renal injury. A kidney injury mouse model is established through a ZEN infected mouse, and lactobacillus plantarum GUANKE powder is fed into the stomach of the kidney injury mouse, so that compared with a model group, the serum, kidney function, antioxidant enzyme activity and kidney related inflammation indexes of the mouse fed with the lactobacillus plantarum GUANKE are correspondingly improved; and the effect of high-dose treatment of the lactobacillus plantarum GUANKE is more remarkable than that of low-dose treatment of the lactobacillus plantarum GUANKE. In addition, the tissue pathological section of the kidney shows that compared with the inflammation, necrosis and lipid degeneration of the mouse tissue of the model group, the inflammation, necrosis and lipid degeneration of the mouse tissue are relieved after the treatment of the lactobacillus plantarum GUANKE. In conclusion, the lactobacillus plantarum GUANKE has the beneficial effects in treating the renal injury.

The invention relates to the technical field of biology, in particular to application of matrix-enabled mesenchymal stem cells, the matrix-enabled mesenchymal stem cells are obtained by culturing and enabling mesenchymal stem cells on a cell culture medium hENFc, and the cell culture medium hENFc is prepared from 1-3 parts of hE-cad-Fc and 1-3 parts of hN-cad-Fc; matrix-enabled mesenchymal stem cells can promote cell nucleus transfer of beta-catenin, enhance multiplication capacity and stemness maintenance capacity of in-vitro amplification and delay cell senescence and apoptosis, and hMSCs subjected to long-term enabled culture (fifteenth generation and above) of hENFc do not have tumorigenicity, do not have any adverse effect on animals and meet the clinical application standard of hMSCs; the traditional Chinese medicine composition can be used for treating immune disorder diseases, such as systemic lupus erythematosus, diabetic nephropathy, systemic sclerosis and xerosis, and has a wide application prospect.

The invention discloses an application of purple bud tea in preparation of a medicine for improving metabolic disorders, belongs to the technical field of traditional Chinese medicines, and particularly relates to an application of purple bud tea, an extract of purple bud tea or a pharmaceutical composition of purple bud tea in preparation of a medicine for improving metabolic disorders. The purple bud tea extract disclosed by the invention can improve uric acid level rise caused by metabolic disorder, and has good prevention and treatment effects on metabolic disorder caused by sugar, fat and uric acid level rise caused by high-fat and high-sugar diet.